Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & amp; EVOLVE-2)

ConclusionsGalcanezumab was as effective in patients with HFEM as in those with LFEM. Associated symptoms, quality of life, and disability were similarly improved in patients with HFEM or LFEM.Trial registrationNCT02614183,NCT02614196.

http://link.springer.com/10.1186/s10194-019-1024-x

Source: The Journal of Headache and Pain - June 27, 2019 Category: Neurology Source Type: research